| Secondary Neoplasm studied in …STUDIED_INderived200 of 7,778show all (up to 200) |
|---|
| → studied in | NCT00423306Phase 2 · completed A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02743741NA · completed Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Ovarian Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03598257Phase 2 · active not recruiting Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Collecting Duct Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03897543Phase 1/Phase 2 · completed ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04175912Phase 2 · active not recruiting Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04267848Phase 3 · recruiting Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04548752Phase 2 · active not recruiting Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04605913Phase 1/Phase 2 · active not recruiting Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05057247Phase 2 · completed Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05176223Phase 2 · completed 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Endometrial Mixed Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05273554Phase 1 · completed A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05877599Phase 1 · recruiting A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05891171Phase 1 · active not recruiting Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06058377Phase 3 · recruiting Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06406465Phase 2 · recruiting A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06589804Phase 3 · recruiting Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06605664Phase 2 · recruiting Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07011719Phase 3 · recruiting Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07061977Phase 3 · recruiting Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Cervical Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07472322Phase 1/Phase 2 · not yet recruiting ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07574541Phase 2 · not yet recruiting Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07607769recruiting MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment. · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07667400Phase 1/Phase 2 · not yet recruiting Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07671417early Phase 1 · recruiting Imaging Study in Metastatic Clear Cell RCC. · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07705035Phase 1 · recruiting DBC-664 in Adult Patients With Solid Tumors · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07744126Phase 2 · recruiting A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07770802Phase 1 · recruiting Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07845617recruiting Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07847060NA · not yet recruiting Hypofractionated Radiotherapy in Older Adults With Head and Neck Squamous Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07847671Phase 2 · not yet recruiting Fecal Microbiota Transplantation With QL1706 Plus Bevacizumab for Advanced HCC · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07848243Phase 2 · recruiting Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Cervical Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00646022recruiting Natural History of Familial Carcinoid Tumor · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04071223Phase 2 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04086485Phase 1/Phase 2 · recruiting Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04644770Phase 1 · active not recruiting A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Endometrial Mixed Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05540925completed Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05956093NA · active not recruiting 68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06120283Phase 1 · recruiting BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06388967recruiting Pancreatic Cancer Detection Consortium · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06726161Phase 1/Phase 2 · recruiting Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227012Phase 1/Phase 2 · recruiting Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07305428NA · recruiting Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07594106Phase 1/Phase 2 · recruiting REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07621718Phase 3 · recruiting Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07691762Phase 3 · not yet recruiting A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07733024Phase 2 · recruiting Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07844057Phase 2 · not yet recruiting First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Small Intestinal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07844551Phase 2 · not yet recruiting ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC · condition mapped PROBABILISTIC · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07845266Phase 1 · completed Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02498613Phase 2 · active not recruiting A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04123379Phase 2 · active not recruiting Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04216732recruiting Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Thyroid Gland Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04858334Phase 2 · recruiting APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Acinar Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05136196Phase 2 · recruiting BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564390Phase 2 · recruiting MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Acute Myeloid Leukemia Arising from Previous Myelodysplastic/Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583708Phase 2 · recruiting Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05922930Phase 1/Phase 2 · active not recruiting Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06084234Phase 4 · recruiting National Liver Cancer Screening Trial · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06369610Phase 2 · active not recruiting Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06385080Phase 1/Phase 2 · recruiting A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06496178Phase 3 · active not recruiting A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06525220Phase 3 · active not recruiting A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06618664Phase 3 · recruiting A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02) · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06737913Phase 2 · recruiting HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06980038Phase 2 · recruiting Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07124000recruiting DESTINY-PANTUMOUR04 · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07142005recruiting Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Thyroid Gland Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07219212Phase 1 · recruiting A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07259317Phase 2 · recruiting Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07276399Phase 3 · recruiting A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07458906NA · recruiting DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07489066Phase 2 · recruiting Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07562152Phase 3 · recruiting Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07670312Phase 1/Phase 2 · recruiting Evaluation of XYA02 in Patients With Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07748988Phase 1 · recruiting Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02293954NA · active not recruiting Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Thyroid Gland Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04145141completed National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04570956Phase 2 · terminated Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Breast Lobular Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04844073Phase 1/Phase 2 · terminated A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05237934recruiting Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05575440terminated Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Thyroid Gland Follicular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05773274Phase 2 · recruiting Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Digestive System Neuroendocrine Tumor G1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06179303Phase 2 · recruiting Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563479Phase 3 · recruiting A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Human Papillomavirus-Related Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07407920Phase 2 · recruiting Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Early Stage Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07408856Phase 1 · recruiting CAN1012 in Pre-Malignant DCIS and LCIS · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Breast Lobular Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07838415recruiting Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07839767recruiting Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrence · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07840001Phase 2 · not yet recruiting Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07840092recruiting Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05814549active not recruiting A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC) · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06253650Phase 2 · recruiting Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06915753Phase 1 · recruiting Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07012044Phase 1 · recruiting A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Acute Myeloid Leukemia Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07025369Phase 2 · recruiting Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07291076Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07344220Phase 2 · enrolling by invitation Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07835737Phase 1/Phase 2 · not yet recruiting Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07836309not yet recruiting TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07836530Phase 3 · not yet recruiting Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07836712Phase 2 · not yet recruiting Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00001595recruiting An Investigation of Pituitary Tumors and Related Hypothalmic Disorders · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Lactotroph Pituitary Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01660984active not recruiting Natural History Study of Children and Adults With Medullary Thyroid Cancer · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Thyroid Gland Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02314169Phase 2 · active not recruiting Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Anal Canal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02471352recruiting Studies of Dermatologic Diseases Biospecimen Acquisition Protocol · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03375320Phase 3 · active not recruiting Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Digestive System Neuroendocrine Tumor G1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03965689Phase 2 · active not recruiting Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04079712Phase 2 · active not recruiting Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04522570NA · completed Thermal Ablation of Cervical Metastases From Thyroid Carcinoma · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Thyroid Gland Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04671667Phase 2 · recruiting Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04810078Phase 3 · active not recruiting A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05172245Phase 1 · recruiting Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Carcinoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05554406Phase 2 · recruiting Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Acute Myeloid Leukemia Arising from Previous Myelodysplastic/Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05913388Phase 2 · active not recruiting GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05977907Phase 2 · active not recruiting Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06066138Phase 1 · recruiting A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06109272Phase 2/Phase 3 · active not recruiting A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06814496Phase 1/Phase 2 · recruiting Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Thyroid Gland Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06858813Phase 1 · recruiting A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06863311Phase 2 · recruiting Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07006727Phase 1 · recruiting Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Thymus Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07278479Phase 1/Phase 2 · recruiting Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07409272Phase 3 · recruiting A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07488676Phase 1/Phase 2 · recruiting A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07565740Phase 1 · recruiting Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07596134NA · not yet recruiting Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07833085NA · not yet recruiting CAIX-targeted PET/CT in Solid Tumors · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07833839Phase 3 · not yet recruiting ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02620852NA · recruiting Women Informed to Screen Depending on Measures of Risk (Wisdom Study) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Breast Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03635892Phase 2 · active not recruiting A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Unclassified Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04216316Phase 1/Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04534205Phase 2/Phase 3 · active not recruiting A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04543071Phase 2 · active not recruiting Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05172258Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05878288Phase 2 · active not recruiting Deep sequencIng in Cutaneous Squamous CEll caRciNomas · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Cutaneous Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Fallopian Tube Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05983432Phase 1 · recruiting Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06005740Phase 1 · active not recruiting A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06021626Phase 1 · recruiting A Study of CRD3874-SI in People With Solid Tumors · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06040099Phase 2 · active not recruiting A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06176989Phase 2 · recruiting Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06736379Phase 1 · recruiting Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06929845NA · recruiting Organoid Models of Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07639138Phase 2 · recruiting Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07793695Phase 2 · recruiting Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07829926Phase 2 · not yet recruiting Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07831083completed Skin Cancer Among Outdoor Workers · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07831330Phase 2 · not yet recruiting Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07832006Phase 2 · recruiting Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07832227Phase 2 · not yet recruiting Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Ovarian Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03391869Phase 3 · active not recruiting Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03950609Phase 2 · active not recruiting Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04053842Phase 2 · completed Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04234568Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04985565NA · active not recruiting Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06161545Phase 2 · recruiting Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06954116Phase 2 · recruiting Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07147361active not recruiting Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Cervical Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07627191early Phase 1 · recruiting GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07650240Phase 2 · recruiting Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07688187Phase 1 · recruiting A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07827807Phase 2 · not yet recruiting PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07827872Phase 3 · not yet recruiting Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07828236Phase 1 · not yet recruiting PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07828249Phase 1 · not yet recruiting Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02851784Phase 2/Phase 3 · recruiting Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04105270Phase 2 · recruiting RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04152499Phase 1/Phase 2 · active not recruiting Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544111Phase 2 · active not recruiting PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Thyroid Gland Follicular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665739Phase 2 · recruiting Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Functioning Lung Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05003752Phase 1/Phase 2 · active not recruiting Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05252585Phase 4 · active not recruiting A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Kidney Angiomyolipoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05616650Phase 2 · recruiting Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05665738NA · recruiting Two-fraction HDR Monotherapy for Localized Prostate Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06205316Phase 3 · active not recruiting SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06816394Phase 2 · recruiting Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06916624recruiting Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07020117Phase 1 · recruiting A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07027436Phase 3 · recruiting Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma. · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07109726Phase 1/Phase 2 · recruiting A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07172802Phase 1/Phase 2 · recruiting A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227415Phase 1/Phase 2 · recruiting Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07349537Phase 1 · recruiting Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07572864Phase 2 · recruiting Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC · condition mapped ONTOLOGY_EXACT · 7,778 trials mapped (2,637 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07576725Phase 2 · not yet recruiting Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07625644Phase 3 · recruiting BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Small Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07824583NA · recruiting A Study Evaluating a New Radiation Treatment Workflow (NGDS) · condition mapped ALIAS · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07824765not yet recruiting Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026) · condition mapped CURATED_BROADER · 7,778 trials mapped (2,637 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |